Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study

Won-Il Choi; Sun Hyo Park; Byeong Ju Park; Choong Won Lee

doi:10.4143/crt.2017.119

Articles

Page Path: HOME > Cancer Res Treat > Volume 50(2); 2018 > Article

Original Article Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study: Won-Il Choi, MD, PhD^1,, Sun Hyo Park, MD¹, Byeong Ju Park, MSc², Choong Won Lee, MD, PhD³; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(2):374-381.
DOI: https://doi.org/10.4143/crt.2017.119
Published online: May 8, 2017

¹Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea

²Department of Statistics, Kyungpook National University, Daegu, Korea

³Department of Occupational & Environmental Medicine, Sungso Hospital, Andong, Korea

Correspondence: Won-Il Choi, MD, PhD Department of Internal Medicine, Keimyung University School of Medicine, 56 Dalseong-ro, Jung-gu, Daegu 41931, Korea
Tel: 82-53-250-7572 Fax: 82-53-250-8379 E-mail: choi_wi@hanmail.net

*Won-Il Choi and Sun Hyo Park contributed equally to this work.

• Received: March 7, 2017 • Accepted: April 25, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,016 Views
529 Download
37 Web of Science
36 Crossref
37 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
In this nationwide 5-year longitudinal population-based study, we aimed at investigating the incidence of lung cancer among patients with interstitial lung disease.
Materials and Methods
Data was collected from the Korean National Health Insurance Research Database from 49,773,195 Korean residents in 2009. Thirteen thousand six hundred and sixty-six patients with interstitial lung disease diagnosed January-December 2009. The end of follow-up was June 30, 2014. Up to four matching chronic obstructive pulmonary disease controls were selected to compare the lung cancer high-risk group based on age, sex, diagnosis date (within 30 days), and hospital size. The number of patients with newly developed lung cancer was determined.
Results
The incidences of lung cancer were 126.98, 156.62, and 370.38 cases per 10,000 person-years (2,732, 809, and 967 cases of cancer, respectively) in the chronic obstructive pulmonary disease, interstitial lung disease, and chronic obstructive pulmonary disease with interstitial lung disease groups, respectively. Of the 879 patients with idiopathic pulmonary fibrosis, 112 developed lung cancer (incidence, 381.00 cases per 10,000 person-years).
Conclusion
Incidence of lung cancer among patients with interstitial lung disease was high. Interstitial lung diseases have a high potential for developing into lung cancer, even when concurrent with chronic obstructive pulmonary disease.
Key words: Incidence, Interstitial lung diseases, Longitudinal studies, Lung neoplasms, Chronic obstructive pulmonary disease

Introduction

Interstitial lung disease (ILD) is characterized continuous accumulation and rapid proliferation of differentiated fibroblasts in regions of repeated epithelial injury along with increased resistance to apoptosis [1]. Repetitive inflammation can lead to multiple genetic alterations affecting cellular growth, differentiation, and survival, including mutation of tumour suppressor genes (e.g., p53), activation of oncogenes, and transformation of apoptotic genes [2]. Idiopathic pulmonary fibrosis (IPF) and lung cancer exhibit similar aberrant tissue repair responses in relation to injury [3] as well as fibroblast behaviour [4].

While the findings of previous studies indicating a high prevalence of lung cancer among patients with IPF [5-9] support a fibrosis–cancer association, they only reflect an association between IPF and cancer, and not a causal relationship. A cohort study demonstrated that the cumulative incidence of lung cancer in patients with IPF increases over time [10]. Therefore, we suspected that ILD developing from a fibrosis background would demonstrate similar clinical characteristics as IPF in relation to lung cancer.

To identify a meaningful number of patients with lung cancer from among those with orphan ILD, it is necessary to deal with large-scale epidemiologic data, such as those included in a national insurance database. Korea has only one health insurance system—the National Health Insurance (NHI) service. Therefore, evaluation of a large number of patients with ILD included in the NHI database, along with their follow-up data, would allow us to investigate the relationship between ILD and lung cancer.

To test our hypothesis that ILD would exhibit a greater potential for developing into lung cancer than chronic obstructive pulmonary disease (COPD), we investigated the incidence of lung cancer as a surrogate endpoint of lung fibrosis, which might be a major characteristic of ILD.

Materials and Methods

1. Study subjects

This retrospective cohort study included data collected from the NHI system. Since each citizen in Korea has a unique resident registration number, data duplication is avoided. The NHI service—the only public insurance system operated by the Ministry of Health and Welfare in Korea [11,12]—is compulsory and covers the entire population, without exceptions for seasonal or part-time workers or unemployed persons.

This study adhered to the Declaration of Helsinki. The present study was approved by the Institutional Review Board of Keimyung University Dongsan Hospital, Keimyung University School of Medicine (2015-05-006). The need for written informed consent was waived.

2. Case identification

According to the National Statistical Office of Korea, the mid-year population size of people ≥ 40 years of age in 2009 was 22,280,691. Individuals from the whole population (≥ 40 years) and patients with COPD were selected as control subjects. Patients with ILD and COPD between January and December 2009 were enrolled.

Selection was performed automatically by a computer program developed by one of the authors using the SAS ver. 9 (SAS Institute Inc., Cary, NC). The International Classification of Diseases, 10th revision (ICD-10) is used as a key reference not only in disease diagnosis but also within the NHI database.

All of the cases and controls were identified between January and December 2009, and were followed up until June 2014. The diagnostic codes of lung cancer cases diagnosed before 2009 are maintained on the NHI database. New lung cancer cases were identified by counting new cases registered during the calendar year excluding preexisting lung cancers. We counted newly developed lung cancer cases after one month of recruiting ILD and COPD cases to exclude cases simultaneously diagnosed as both ILD and lung cancer.

3. Definition of ILD

Based on the ICD-10 definition, ILD was defined by the code J84 for other ILD, excluding drug-induced ILDs, interstitial emphysema, and lung diseases caused by external agents. In order to select ILD without specific related diseases, connective tissue disease-related ILD, hypersensitivity pneumonitis, and sarcoidosis were not included in the present cohort. The code J84.1 was used to define ILD with fibrosis, excluding chronic pulmonary fibrosis due to inhalation of chemicals, gases, fumes, or vapours or that occurring following radiation therapy during the study period (Fig. 1). Patients identified with both codes (J84.9 and J84.1) were classified under J84.1.

The Korean NHI service introduced a specific code, J84.1A, for IPF, which has been implemented since 2009. When a patient is registered under this code, the physician is required to submit the necessary eligibility documents to the NHI service.

4. General population and patients with COPD as control subjects

Because COPD mostly develops as a result of cigarette smoking, patients with COPD classified under codes J43 and J44 were included as control subjects in order to assess the effect of smoking on development of lung cancer. Since the NHI database does not include data regarding smoking history, COPD was considered a surrogate for smoking in the present study.

Of the 567,652 patients diagnosed with COPD between January and December 2009, 11,256 were excluded for having simultaneous ILD. For every patient with ILD, up to four control subjects with COPD, matched for age (within 1 year), sex, initiation date (within 30 days), and hospital size, were included. Index dates for control subjects were defined by those of the corresponding matched test subjects. Patients with simultaneous COPD and ILD (COPD+ILD group) were distinguished from those with COPD alone; patient selection for these two groups was performed by the same selection algorithm as that applied for the ILD group (Fig. 1). From among the 11,256 patients with concomitant COPD and ILD, 8,012 were included in the present study.

In order to determine the baseline incidence of lung cancer in Korea, incidence of lung cancer during the study period was calculated in a random sample (n=343,684) derived from the general population (≥ 40 years of age) provided by NHI, accounting for approximately 2.2% of the entire population [13].

5. Data validation

For a patient to be registered as having lung cancer (C34) and be eligible for subsidized care, physicians are required to submit the necessary documents to the Health Insurance Review and Assessment (HIRA) database. All patients with cancer are registered in a separate national cancer database maintained by the National Cancer Center and strictly validated before final registration. Patients who change their lung cancer diagnosis status are excluded from the cancer registry.

6. Statistical analysis

Incidence rates of lung cancer per 10,000 person-years and the corresponding 95% confidence intervals were calculated for patients with ILD and COPD with and without ILD according to age group [14]. Incidence rates were compared with relative risk of lung cancer among different age groups, with the 50- to 59-year-old group of patients as reference. Kaplan-Meier curves were used to compare incidences of lung cancer among patients with ILD, IPF and COPD with and without ILD. The Kaplan-Meier curve for incidence of lung cancer in the general population (≥ 40 years of age) was calculated for comparison. All analyses were performed using SAS ver. 9.

Results

1. Patients with ILD and control subjects

A total of 55% of patients with ILD and COPD controls were men. The median ages of the patients with ILD and those of the COPD controls were 68 years. Nineteen point eight percent of patients with ILD and 18.6% of COPD controls had diabetes (Table 1).

2. Incidence of lung cancer among patients with ILD and COPD

Frequency of lung cancer among the different groups varied according to the definition of ILD (Table 2).

While patients with ILD exhibited 156.62 cases per 10,000 person-years incidence of lung cancer, those with IPF showed 381.00 cases per 10,000 person-years (Fig. 2). The incidence of lung cancer increased according to age within each definition of ILD, with the exception of IPF, in which, the incidence of lung cancer decreased after 70-79 years of age.

The Kaplan-Meier curves demonstrated that the increase in incidence of lung cancer among patients with ILD was greater compared to that among patients with COPD without or with ILD (Fig. 2).

Incidence of lung cancer among patients with COPD without ILD (126.98 cases per 10,000 person-years) was lower compared to that among patients with ILD (156.62 cases per 10,000 person-years) (Table 2). However, the incidence of lung cancer among patients with concomitant COPD and ILD (370.38 cases per 10,000 person-years) was nearly 3 times that among patients with COPD alone (Table 2). The Kaplan-Meier curves demonstrated that patients with concomitant COPD and ILD exhibited the greatest potential for developing lung cancer over the follow-up period, which corresponded with the findings of the IPF group (Fig. 2).

Standard incidence ratios for lung cancer in the ILD, COPD, IPF, and COPD with ILD groups relative to that among the general population were 3.6, 2.8, 8.0, and 7.0, respectively (Table 3).

Regardless of age, the relative risk of lung cancer among patients with ILD was greater compared to that among patients with COPD alone (Table 4).

Discussion

In the present study, incidence of lung cancer among patients with ILD was found to be 1.2 times that among patients with COPD. Incidences of lung cancer among patients with concomitant COPD with ILD and IPF were 2.9 and 2.4 times those among patients with COPD alone and ILD, respectively. These findings demonstrate that ILD have a high potential for the development of lung cancer. The greater incidence of lung cancer among patients with concomitant COPD with ILD in comparison with that among patients with COPD alone suggests that ILD might contribute to the development of lung cancer.

In Korea, the proportion of smokers among patients with COPD (68%) [15] is comparable to that among patients with IPF (64%) [16]. Although it is not appropriate to directly compare these values with the present findings, these data suggest that IPF might have a relatively high potential for progressing to lung cancer.

In a U.S. lung cancer screening trial, the 5-year cumulative incidence of lung cancer among former/current smokers with a smoking history of over 30 pack-years was found to be approximately 64.5 per 10,000 person-years [17]. Among patients with COPD, the incidence of cancer among a mean 58-pack-year smoker cohort was 167 cases per 10,000 person-years [18]. In the present study, over a follow-up period of approximately 5 years, the incidences of lung cancer among patients with ILD and IPF were 156 and 381 per 10,000 person-years, respectively. The incidence of lung cancer among patients with ILD in the present study was 2 times that reported among the 30-pack-year smoker cohort in the U.S. lung cancer screening and similar to that reported among the 58-pack-year smoker cohort of patients with COPD. The median age of COPD in the present study was 66, which is similar to COPD cohort study [18]. We hope that these findings encourage future screening studies among patients with ILD to ensure early detection of lung cancer, thus eventually decreasing the mortality rate.

In the present study, patients with COPD alone developed lung cancer at a rate of 126 per 10,000 person-years, while the corresponding value among patients with concomitant COPD and ILD was 370 per 10,000 person-years—an almost 3-fold higher chance of developing lung cancer in comparison with that in patients with COPD alone. In a cohort study of smokers, interstitial lung abnormalities, accompanied by reduced total lung capacity, were observed in 12.5% of participants [19]. In the COPD cohort study, lung cancer diagnosis exhibited a greater association with decline in diffusion capacity than with decline in lung volume [18]. In patients with combined pulmonary fibrosis and emphysema (CPFE), cancer arises in fibrotic areas rather than emphysematous spaces [20,21]. The risk of lung cancer among patients with CPFE and IPF was reported to be comparable and greater in comparison with that among patients with emphysema [22]. Since CPFE is now considered a distinctive disease entity [23], it is important to evaluate the incidence of lung fibrosis among patients with COPD in relation to lung cancer diagnosis. Taken together, these findings suggest that fibrosis—regardless of whether the diagnosis is based on computed tomography findings, lung volume or diffusion capacity, or diagnostic codes—might contribute to development of lung cancer.

The most important limitation of this study is that, because the HIRA database does not include data regarding smoking history, we could not control for the confounding effects of smoking on development of lung cancer. We did not take into consideration of some potential co-morbidities that may influence on the incidence of lung cancer. However, we compared the incidence of lung cancer between patients with ILD and COPD, for which smoking is a major contributor.

Another limitation of the present study is that the diagnoses of ILD and other co-morbidities were defined based on ICD codes, which may be inaccurate compared with the diagnoses obtained from a medical chart, and underreporting of asymptomatic ILD or misclassification was also possible. This database of national insurance claim data does not have identification numbers. Therefore, it was impossible to validate individual cases through a chart review. We may have underestimated the ILD incidence because of inaccurate ILD data. However, the prevalence rate of ILD (> 40 years) in the present study was 61.3 cases per 100,000 per year, which is quite a similar to the previous ILD prevalence study [24] as well as broad definition of ILD with fibrosis when age is adjusted [25].

The present study may be affected by selection bias because the controls were also identified based on medical claims. Thus, the controls were more likely to have comorbidities than controls selected from the general population. Although we excluded patients with a diagnosis of lung cancer before and 1 month after index date, patients with lung cancer could be miscounted as new cases in the early period of cohort. In addition, other risk factors, such as pulmonary function and high-resolution computed tomography findings for ILD, could not be evaluated because of the NHI primarily included medical claims.

ILD has a significant relationship with lung cancer, even in patients with underlying COPD. Greater attention must be paid to the possibility of development of lung cancer in patients with ILD.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIP) (No. 2014R1A5A2010008).

Fig. 1.

Flow chart of the study. Patient selection flow chart for interstitial lung disease (ILD) (A) and chronic obstructive pulmonary disease (COPD) (B). ICD-10, International Classification of Disease, 10th revision.

Fig. 2.

Cumulative incidence curve of lung cancer by Kaplan-Meier analysis. General population (blue line), ILD (red line), COPD (green line), IPF (orange line), and COPD with ILD (gray line). ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis.

Table 1.

Demographic and clinical characteristics of patients with ILD, COPD (matching control), IPF, COPD with ILD, and general population

Characteristic	General population (n=343,684)	ILD (n=13,666)	COPD (matching control, n=54,640)	IPF (n=879)	COPD with ILD (n=8,012)
Sex
Male	58,275 (46.0)	7,524 (55.0)	30,089 (55.0)	555 (63.1)	5,699 (71.1)
Female	85,409 (53.9)	6,142 (45.0)	24,551 (45.0)	324 (46.9)	2313 (28.9)
Age (yr)
Median (Q1-Q3)	53 (48-63)	66 (56-74)	66 (56-74)	68 (61-74)	71 (64-77)
40-49	140,940 (41.0)	1,707 (12.5)	6,421 (11.7)	40 (4.6)	292 (3.6)
50-59	88,883 (25.8)	2,830 (20.7)	10,900 (19.9)	151 (17.2)	972 (12.1)
60-69	69,604 (20.2)	3,829 (28.0)	15,557 (28.4)	294 (33.4)	2,410 (30.1)
70-79	33,520 (9.7)	3,765 (27.6)	15,553 (28.4)	319 (36.3)	3,112 (38.8)
≥ 80	10,737 (3.1)	1,535 (11.2)	6,209 (11.3)	75 (8.5)	1,226 (15.3)
Other baseline cormobidities
Malignancy (C00-C97) except lung cancer (C34)	9,543 (2.7)	791 (2.8)	4,134 (7.6)	24 (2.7)	591 (7.4)
Diabetes (E10-E14)	39,485 (11.4)	2,709 (19.8)	10,162 (18.6)	157 (17.9)	1,950 (24.3)
Chronic renal failure (N17-N19)	1,679 (0.5)	255 (1.9)	884 (1.6)	8 (0.9)	175 (2.2)
Hypertension (I10)	69,290 (20.1)	4,372 (32.0)	18,414 (33.7)	202 (23.0)	3,021 (37.7)
Previous thromboembolism (I80.2, I80.3, I26, I26.0, I26.9, I81, I82, I82.0, I82.8, I82.9)	470 (0.1)	63 (0.5)	276 (0.5)	1 (0.1)	70 (0.9)
Previous myocardial infarction (I21, I22, I23, I25.2)	2,659 (0.8)	222 (1.6)	931 (1.7)	9 (1.0)	246 (3.1)

Values are presented as number (%) unless otherwise indicated. Summarized based on the diagnosis at the top of the lists of International Statistical Classification of Diseases and Related Health Problems, 10th edition (ICD-10) codes of respiratory diseases. ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis.

Table 2.

Age distribution of lung cancer incidence per 10,000 person-years in general population and patients with ILD, IPF, COPD (matching control), COPD with ILD

	No.	No. of lung cancer cases	Person-years of follow-up	Incidence	95% CI
General population (yr)
40-49	140,940	567	685,094	8.28	16.05-18.93
50-59	88,883	878	444,041	19.77	39.42-45.00
60-69	69,604	1,375	346,584	39.67	84.79-94.25
70-79	33,520	1,104	157,990	69.88	179.96-202.53
≥ 80	10,737	368	41,778	88.08	259.48-318.53
Total	343,684	4,292	1,675,489	25.62	55.05-58.45
ILD (yr)
0-49	1,707	30	7,086	42.34	27.19-57.49
50-59	2,830	111	11,701	94.86	77.21-112.51
60-69	3,829	262	15,069	173.86	152.81-194.92
70-79	3,765	303	13,343	227.09	201.52-252.66
≥ 80	1,535	103	4,452	231.33	186.66-276.01
Total	13,666	809	51,652	156.62	145.83-167.42
COPD (yr)
40-49	6,421	100	26,816	37.29	29.98-44.60
50-59	10,900	331	45,923	72.08	64.31-79.84
60-69	15,557	822	64,015	128.41	119.63-137.18
70-79	15,553	1,123	58,909	190.63	179.48-201.78
≥ 80	6,209	356	19,483	182.73	163.74-201.71
Total	54,640	2,732	215,146	126.98	122.22-131.75
IPF (yr)
40-49	40	2	157	127.25	0.00-303.60
50-59	151	16	584	273.82	139.65-408.00
60-69	294	42	1,018	412.71	287.89-537.53
70-79	319	45	963	467.21	330.70-603.72
≥ 80	75	7	217	322.14	83.49-560.78
Total	879	112	2,940	381.00	310.44-451.56
COPD with ILD (yr)
40-49	292	12	1,136	105.64	45.87-165.41
50-59	972	90	3,686	244.19	193.74-294.64
60-69	2,410	303	8,587	352.84	313.11-392.57
70-79	3,112	420	9,676	434.06	392.55-475.57
≥ 80	1,226	142	3,024	469.64	392.40-546.89
Total	8,012	967	26,109	370.38	347.03-393.72

ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary disease; CI, confidence interval.

Table 3.

Incidence rates (per 10,000) and RRs for lung cancer in interstitial lung diseases and COPD by age compared to general population

Age group (yr)	General population	ILD	RR (95% CI)	COPD	RR (95% CI)
40-49	8.28	42.34	5.11 (3.54-7.38)	37.29	4.50 (3.64-5.57)
50-59	19.77	94.86	4.80 (3.94-5.85)	72.08	3.65 (3.21-4.14)
60-69	39.67	173.86	4.38 (3.84-5.00)	128.41	3.24 (2.97-3.53)
70-79	69.88	227.09	3.25 (2.86-3.69)	190.63	2.73 (2.51-2.96)
≥ 80	88.08	231.33	2.63 (2.11-3.27)	182.73	2.07 (1.79-2.40)
Total	25.62	156.62	6.11 (5.67-6.59)	126.98	4.96 (4.72-5.20)

RR, relative risk; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; CI, confidence interval.

Table 4.

Incidence rates (per 10,000) and RR for lung cancer in interstitial lung diseases compared to COPD

Age group (yr)	COPD	ILD	RR (95% CI)
40-49	37.29	42.34	1.14 (0.76-1.71)
50-59	72.08	94.86	1.32 (1.06-1.63)
60-69	128.41	173.86	1.35 (1.18-1.56)
70-79	190.63	227.09	1.19 (1.05-1.35)
≥ 80	182.73	231.33	1.27 (1.02-1.58)
Total	126.98	156.62	1.23 (1.14-1.33)

RR, relative risk; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; CI, confidence interval.

REFERENCES

1. Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D. Apoptosis in lung injury and fibrosis. Eur Respir J. 2008;32:1631–8. Article PubMed
2. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517–25. Article PubMed
3. Chambers RC, Mercer PF. Mechanisms of alveolar epithelial injury, repair, and fibrosis. Ann Am Thorac Soc. 2015;12 Suppl 1:S16–20. Article PubMed PMC
4. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev. 2013;22:265–72. Article PubMed PMC
5. Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995;45:925–32. Article PubMed
6. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980;35:496–9. Article PubMed PMC
7. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis: a population-based cohort study. Am J Respir Crit Care Med. 2000;161:5–8. Article PubMed
8. Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J. 1996;89:505–10. Article PubMed
9. Harris JM, Cullinan P, McDonald JC. Does cryptogenic fibrosing alveolitis carry an increased risk of death from lung cancer? J Epidemiol Community Health. 1998;52:602–3. Article PubMed PMC
10. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14:723–8. Article PubMed
11. Kim DS. Introduction: health of the health care system in Korea. Soc Work Public Health. 2010;25:127–41. Article PubMed
12. Kim DS. Special issue on the national health care system of South Korea. Soc Work Public Health. 2010;25:125–6. Article PubMed
13. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46:e15.Article PubMed PDF
14. Szklo M, Nieto FJ. Epidemiology: beyond the basics. Burlington, MA: Jones & Bartlett Learning Burlington; 2014.
15. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med. 2005;172:842–7. Article PubMed
16. Lee SH, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, et al. Association between occupational dust exposure and prognosis of idiopathic pulmonary fibrosis: a Korean national survey. Chest. 2015;147:465–74. Article PubMed
17. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. Article PubMed PMC
18. de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease: incidence and predicting factors. Am J Respir Crit Care Med. 2011;184:913–9. Article PubMed
19. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364:897–906. Article PubMed PMC
20. Girard N, Marchand-Adam S, Naccache JM, Borie R, Urban T, Jouneau S, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients. J Thorac Oncol. 2014;9:1162–70. Article PubMed
21. Minegishi Y, Kokuho N, Miura Y, Matsumoto M, Miyanaga A, Noro R, et al. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. Lung Cancer. 2014;85:258–63. Article PubMed
22. Kwak N, Park CM, Lee J, Park YS, Lee SM, Yim JJ, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014;108:524–30. Article PubMed
23. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234–40. Article PubMed
24. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967–72. Article PubMed
25. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–6. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Air Pollution and Interstitial Lung Disease
Yong Suk Jo, Jin Woo Song
Tuberculosis and Respiratory Diseases.2025; 88(1): 45. CrossRef
Spatial transcriptome analysis of lung squamous cell carcinoma arising from interstitial pneumonia provides insights into tumor heterogeneity
Koto Ukon, Satoshi Nojima, Daisuke Motooka, Tsuyoshi Takashima, Masaharu Kohara, Hiroki Kiyokawa, Kenji Kimura, Eriko Fukui, Shinichiro Tahara, Kansuke Kido, Takahiro Matsui, Yasushi Shintani, Daisuke Okuzaki, Eiichi Morii
Pathology - Research and Practice.2025; 266: 155805. CrossRef
The impact of air pollution on interstitial lung disease: a systematic review and meta-analysis
Doris Lan, Caitlin C. Fermoyle, Lauren K. Troy, Luke D. Knibbs, Tamera J. Corte
Frontiers in Medicine.2024;[Epub] CrossRef
Subsolid Nodules
Lea Azour, Andrea S. Oh, Ashley E. Prosper, Danielle Toussie, Geraldine Villasana-Gomez, Lila Pourzand
Clinics in Chest Medicine.2024; 45(2): 263. CrossRef
Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease
Soo Jin Han, Hyeon Hwa Kim, Dong-gon Hyun, Wonjun Ji, Chang-Min Choi, Jae Cheol Lee, Ho Cheol Kim
BMC Pulmonary Medicine.2024;[Epub] CrossRef
High risk of lung cancer in surfactant-related gene variant carriers
Alexandre Brudon, Marie Legendre, Arthur Mageau, Julien Bermudez, Philippe Bonniaud, Diane Bouvry, Jacques Cadranel, Aurélie Cazes, Bruno Crestani, Tristan Dégot, Céline Delestrain, Rémi Diesler, Ralph Epaud, Quentin Philippot, Nathalie Théou-Anton, Carol
European Respiratory Journal.2024; 63(5): 2301809. CrossRef
Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives
Masaki Hanibuchi, Hirokazu Ogino, Seidai Sato, Yasuhiko Nishioka
The Journal of Medical Investigation.2024; 71(1.2): 9. CrossRef
Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
Fotios Sampsonas, Pinelopi Bosgana, Vasiliki Bravou, Argyrios Tzouvelekis, Foteinos-Ioannis Dimitrakopoulos, Eleni Kokkotou
Genes.2024; 15(7): 934. CrossRef
Predictors for acute exacerbation of interstitial pneumonia following lung cancer surgery: a multicenter study
Lijie Yin, Rui Xu, Xiaojian Liu, Liping Fu, Guangliang Qiang
BMC Pulmonary Medicine.2024;[Epub] CrossRef
Effects of Light-absorbing Carbons in Intraoperative Molecular Imaging–Guided Lung Cancer Resections
Feredun Azari, Gregory Kennedy, Kevin Zhang, Elizabeth Bernstein, Ashley Chang, Bilal Nadeem, Alix Segil, Charuhas Desphande, James Delikatny, John Kucharczuk, Sunil Singhal
Molecular Imaging and Biology.2023; 25(1): 156. CrossRef
Management of Lung Cancer in the Patient with Interstitial Lung Disease
Angela J Frank, Ibiayi Dagogo-Jack, Ioana A Dobre, Sarah Tait, Lana Schumacher, Florian J Fintelmann, Leah M Fingerman, Florence K Keane, Sydney B Montesi
The Oncologist.2023; 28(1): 12. CrossRef
Is pulmonary fibrosis a precancerous disease?
Mahdie Hosseini, Mary Salvatore
European Journal of Radiology.2023; 160: 110723. CrossRef
Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
Jang Ho Lee, Hyung Jun Park, Seonok Kim, Ye-Jee Kim, Ho Cheol Kim
BMC Pulmonary Medicine.2023;[Epub] CrossRef
Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review
Anna Stainer, Antonio Tonutti, Maria De Santis, Francesco Amati, Angela Ceribelli, Gabriele Bongiovanni, Chiara Torrisi, Antonio Iacopino, Giuseppe Mangiameli, Stefano Aliberti, Carlo Selmi
Frontiers in Medicine.2023;[Epub] CrossRef
KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
Junmei Guo, Wei Zhang, Liping Sun, Hongfang Yu, Yuzhe Wang, Li Feng, Hao Yang
Scientific Reports.2023;[Epub] CrossRef
Proteomic analysis of serum in workers exposed to diesel engine exhaust
Mohammad L. Rahman, Bryan A. Bassig, Yufei Dai, Wei Hu, Jason Y. Y. Wong, Batel Blechter, H. Dean Hosgood, Danzhi Ren, Huawei Duan, Yong Niu, Jun Xu, Wei Fu, Kees Meliefste, Baosen Zhou, Jufang Yang, Meng Ye, Xiaowei Jia, Tao Meng, Ping Bin, Debra T. Silv
Environmental and Molecular Mutagenesis.2022; 63(1): 18. CrossRef
Two‐Stage Hybrid Approach of Deep Learning Networks for Interstitial Lung Disease Classification
Swati P. Pawar, Sanjay N. Talbar, Fan Yang
BioMed Research International.2022;[Epub] CrossRef
Improvement in Stage of Lung Cancer Diagnosis With Incidental Pulmonary Nodules Followed With a Patient Tracking System and Computerized Registry
Laurie L. Carr, Debra S. Dyer, Pearlanne T. Zelarney, Elizabeth O. Kern
JTO Clinical and Research Reports.2022; 3(3): 100297. CrossRef
Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges
Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells, Manuela Funke-Chambour
ERJ Open Research.2022; 8(2): 00115-2022. CrossRef
Comorbidity and life expectancy in shared decision making for lung cancer screening
Brett Bade, Mary Gwin, Matthew Triplette, Renda Soylemez Wiener, Kristina Crothers
Seminars in Oncology.2022; 49(3-4): 220. CrossRef
Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis
Amare Abera Tareke, Wondwosen Debebe, Addis Alem, Nebiyou Simegnew Bayileyegn, Taddese Alemu Zerfu, Andualem Mossie Ayana, Kazuyoshi Kuwano
Pulmonary Medicine.2022; 2022: 1. CrossRef
MicroRNAs as early diagnostic biomarkers for non‑small cell lung cancer (Review)
Xindi Liang, Qiang Wu, Yuan Wang, Shirong Li
Oncology Reports.2022;[Epub] CrossRef
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
Ahmad Abu Qubo, Jamil Numan, Juan Snijder, Maria Padilla, John H.M. Austin, Kathleen M. Capaccione, Monica Pernia, Jean Bustamante, Timothy O'Connor, Mary M. Salvatore
Breathe.2022; 18(4): 220147. CrossRef
Shades of Gray
Lea Azour, Jane P. Ko, David P. Naidich, William H. Moore
Chest.2021; 159(5): 2072. CrossRef
Prevalence, incidence and cause-specific mortality of rheumatoid arthritis–associated interstitial lung disease among older rheumatoid arthritis patients
Jeffrey A Sparks, Yinzhu Jin, Soo-Kyung Cho, Seanna Vine, Rishi Desai, Tracy J Doyle, Seoyoung C Kim
Rheumatology.2021; 60(8): 3689. CrossRef
Diagnosis and Management of Fibrotic Interstitial Lung Diseases
Bridget F. Collins, Fabrizio Luppi
Clinics in Chest Medicine.2021; 42(2): 321. CrossRef
Idiopathic Pulmonary Comorbidities and Mechanisms
Maricica Pacurari, Amal Mitra, Timothy Turner, Jian-Dong Li
International Journal of Inflammation.2021; 2021: 1. CrossRef
Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art
Panagiotis Paliogiannis, Sara Solveig Fois, Alessandro Giuseppe Fois, Antonio Cossu, Giuseppe Palmieri, Gianfranco Pintus
Current Medicinal Chemistry.2021; 28(11): 2234. CrossRef
Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?
George E Fragoulis, Katerina Chatzidionysiou
Clinical Rheumatology.2020; 39(3): 957. CrossRef
Pharmacological treatment of pulmonary fibrosis
Won-Il Choi
Journal of the Korean Medical Association.2020; 63(1): 47. CrossRef
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
Paolo Cameli, Elena Bargagli, Laura Bergantini, Miriana d’Alessandro, Maria Pieroni, Giovanni A. Fontana, Piersante Sestini, Rosa Metella Refini
International Journal of Molecular Sciences.2020; 21(17): 6187. CrossRef
Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide population-based study
Won-Il Choi, Dong Yoon Lee, Hyun-Gi Choi, Choong Won Lee
Respiratory Research.2019;[Epub] CrossRef
Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai
Thoracic Cancer.2018; 9(7): 847. CrossRef
Germline mutations in young non-smoking women with lung adenocarcinoma
Iikki Donner, Riku Katainen, Lauri J. Sipilä, Mervi Aavikko, Eero Pukkala, Lauri A. Aaltonen
Lung Cancer.2018; 122: 76. CrossRef
Risk factors for interstitial lung disease: a 9-year Nationwide population-based study
Won-Il Choi, Sonila Dauti, Hyun Jung Kim, Sun Hyo Park, Jae Seok Park, Choong Won Lee
BMC Pulmonary Medicine.2018;[Epub] CrossRef
Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy
Fangjuan Li, Ziyang Zhou, Ailu Wu, Yong Cai, Hongyu Wu, Ming Chen, Shixiong Liang
Radiation Oncology.2018;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study

Cancer Res Treat. 2018;50(2):374-381. Published online May 8, 2017

DOI: https://doi.org/10.4143/crt.2017.119

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study

Fig. 1. Flow chart of the study. Patient selection flow chart for interstitial lung disease (ILD) (A) and chronic obstructive pulmonary disease (COPD) (B). ICD-10, International Classification of Disease, 10th revision.

Fig. 2. Cumulative incidence curve of lung cancer by Kaplan-Meier analysis. General population (blue line), ILD (red line), COPD (green line), IPF (orange line), and COPD with ILD (gray line). ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis.

Fig. 1.

Fig. 2.

Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study

Characteristic	General population (n=343,684)	ILD (n=13,666)	COPD (matching control, n=54,640)	IPF (n=879)	COPD with ILD (n=8,012)
Sex
Male	58,275 (46.0)	7,524 (55.0)	30,089 (55.0)	555 (63.1)	5,699 (71.1)
Female	85,409 (53.9)	6,142 (45.0)	24,551 (45.0)	324 (46.9)	2313 (28.9)
Age (yr)
Median (Q1-Q3)	53 (48-63)	66 (56-74)	66 (56-74)	68 (61-74)	71 (64-77)
40-49	140,940 (41.0)	1,707 (12.5)	6,421 (11.7)	40 (4.6)	292 (3.6)
50-59	88,883 (25.8)	2,830 (20.7)	10,900 (19.9)	151 (17.2)	972 (12.1)
60-69	69,604 (20.2)	3,829 (28.0)	15,557 (28.4)	294 (33.4)	2,410 (30.1)
70-79	33,520 (9.7)	3,765 (27.6)	15,553 (28.4)	319 (36.3)	3,112 (38.8)
≥ 80	10,737 (3.1)	1,535 (11.2)	6,209 (11.3)	75 (8.5)	1,226 (15.3)
Other baseline cormobidities
Malignancy (C00-C97) except lung cancer (C34)	9,543 (2.7)	791 (2.8)	4,134 (7.6)	24 (2.7)	591 (7.4)
Diabetes (E10-E14)	39,485 (11.4)	2,709 (19.8)	10,162 (18.6)	157 (17.9)	1,950 (24.3)
Chronic renal failure (N17-N19)	1,679 (0.5)	255 (1.9)	884 (1.6)	8 (0.9)	175 (2.2)
Hypertension (I10)	69,290 (20.1)	4,372 (32.0)	18,414 (33.7)	202 (23.0)	3,021 (37.7)
Previous thromboembolism (I80.2, I80.3, I26, I26.0, I26.9, I81, I82, I82.0, I82.8, I82.9)	470 (0.1)	63 (0.5)	276 (0.5)	1 (0.1)	70 (0.9)
Previous myocardial infarction (I21, I22, I23, I25.2)	2,659 (0.8)	222 (1.6)	931 (1.7)	9 (1.0)	246 (3.1)

	No.	No. of lung cancer cases	Person-years of follow-up	Incidence	95% CI
General population (yr)
40-49	140,940	567	685,094	8.28	16.05-18.93
50-59	88,883	878	444,041	19.77	39.42-45.00
60-69	69,604	1,375	346,584	39.67	84.79-94.25
70-79	33,520	1,104	157,990	69.88	179.96-202.53
≥ 80	10,737	368	41,778	88.08	259.48-318.53
Total	343,684	4,292	1,675,489	25.62	55.05-58.45
ILD (yr)
0-49	1,707	30	7,086	42.34	27.19-57.49
50-59	2,830	111	11,701	94.86	77.21-112.51
60-69	3,829	262	15,069	173.86	152.81-194.92
70-79	3,765	303	13,343	227.09	201.52-252.66
≥ 80	1,535	103	4,452	231.33	186.66-276.01
Total	13,666	809	51,652	156.62	145.83-167.42
COPD (yr)
40-49	6,421	100	26,816	37.29	29.98-44.60
50-59	10,900	331	45,923	72.08	64.31-79.84
60-69	15,557	822	64,015	128.41	119.63-137.18
70-79	15,553	1,123	58,909	190.63	179.48-201.78
≥ 80	6,209	356	19,483	182.73	163.74-201.71
Total	54,640	2,732	215,146	126.98	122.22-131.75
IPF (yr)
40-49	40	2	157	127.25	0.00-303.60
50-59	151	16	584	273.82	139.65-408.00
60-69	294	42	1,018	412.71	287.89-537.53
70-79	319	45	963	467.21	330.70-603.72
≥ 80	75	7	217	322.14	83.49-560.78
Total	879	112	2,940	381.00	310.44-451.56
COPD with ILD (yr)
40-49	292	12	1,136	105.64	45.87-165.41
50-59	972	90	3,686	244.19	193.74-294.64
60-69	2,410	303	8,587	352.84	313.11-392.57
70-79	3,112	420	9,676	434.06	392.55-475.57
≥ 80	1,226	142	3,024	469.64	392.40-546.89
Total	8,012	967	26,109	370.38	347.03-393.72

Age group (yr)	General population	ILD	RR (95% CI)	COPD	RR (95% CI)
40-49	8.28	42.34	5.11 (3.54-7.38)	37.29	4.50 (3.64-5.57)
50-59	19.77	94.86	4.80 (3.94-5.85)	72.08	3.65 (3.21-4.14)
60-69	39.67	173.86	4.38 (3.84-5.00)	128.41	3.24 (2.97-3.53)
70-79	69.88	227.09	3.25 (2.86-3.69)	190.63	2.73 (2.51-2.96)
≥ 80	88.08	231.33	2.63 (2.11-3.27)	182.73	2.07 (1.79-2.40)
Total	25.62	156.62	6.11 (5.67-6.59)	126.98	4.96 (4.72-5.20)

Age group (yr)	COPD	ILD	RR (95% CI)
40-49	37.29	42.34	1.14 (0.76-1.71)
50-59	72.08	94.86	1.32 (1.06-1.63)
60-69	128.41	173.86	1.35 (1.18-1.56)
70-79	190.63	227.09	1.19 (1.05-1.35)
≥ 80	182.73	231.33	1.27 (1.02-1.58)
Total	126.98	156.62	1.23 (1.14-1.33)

Table 1. Demographic and clinical characteristics of patients with ILD, COPD (matching control), IPF, COPD with ILD, and general population

Table 2. Age distribution of lung cancer incidence per 10,000 person-years in general population and patients with ILD, IPF, COPD (matching control), COPD with ILD

ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary disease; CI, confidence interval.

Table 3. Incidence rates (per 10,000) and RRs for lung cancer in interstitial lung diseases and COPD by age compared to general population

RR, relative risk; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; CI, confidence interval.

Table 4. Incidence rates (per 10,000) and RR for lung cancer in interstitial lung diseases compared to COPD

RR, relative risk; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; CI, confidence interval.